Leading the Way in Life Science Technologies

GEN Exclusives

More »

April 15, Vol. 28, No. 8

  • Feature Articles

    • Cell-Based Assay R&D Role Expands
    • Kathy Liszewski
    • Cell-based assays have become a quick, lower-cost means of testing drug candidates for toxic effects in early discovery work Informa Life Sciences’ upcoming “Cell-Based Assays” meeting will highlight some advances that are driving the field such as improved screening technologies, ... more »
    • Emerging Firms Highlighted at Roth Meeting
    • Ilene Schneider
    • T-cell therapy, oxidative stress, lipidomics, and parthenogenesis were some of the concepts discussed at the “20th Annual OC Growth Stock Conference” presented by Roth Capital Partners recently Therapeutic antibody sales have increased significantly over the last decade The market ... more »
    • HTS Carving Out Hit-to-Lead Position
    • Nina Flanagan
    • Pressure to discover more hits and develop more blockbuster drugs with less time and expense spent on target screening continues to spur companies to invest in high-throughput technologies earlier in the drug discovery process In addition, there is a trend ... more »
    • Roche All Set to Launch xCELLigence System
    • John Sterling
    • Beginning this summer, Roche Applied Science will launch the first of three novel, cell-based assay systems under the xCELLigence™ brand name The products are built upon and represent improved versions of the current impedance-based RT-CES technology Roche acquired from Acea ... more »
    • Increasing Yield in Nucleic Acid Sample Prep
    • Vicki Glaser
    • Extraction and purification of nucleic acids from biological materials, whether for research use such as genomic analysis, gene-expression studies, and genotyping or clinical applications like pharmacogenomics, diagnostic and prognostic use, or forensics, involve many of the same challenges These include ... more »
    • Managing Data from Next-Gen Sequencing
    • William Van Etten
    • Using novel sequencing chemistries, microfluidic systems, and reaction-detection methods, next-generation sequencing vendors offer 100- to 1,000-fold increased throughput and 100-to 1,000-fold decreased cost as compared to conventional Sanger DNA sequencing Where high-throughput sequencing was previously limited to top sequencing ... more »